<DOC>
	<DOCNO>NCT00611858</DOCNO>
	<brief_summary>The standard treatment rectal cancer receive chemotherapeutic drug 5-fluorouracil ( 5-FU ) radiation therapy surgery remove rectal cancer . This know neoadjuvant chemoradiotherapy . The purpose research study determine Cetuximab improve benefit neoadjuvant chemoradiotherapy give 5-FU radiation therapy . The epidermal growth factor ( EGF ) receptor , find rectal cancer , specific part cancer felt encourage tumor growth . Cetuximab target block EGF receptor show safe effective treating colorectal cancer head neck cancer .</brief_summary>
	<brief_title>Cetuximab , 5-FU Radiation Neoadjuvant Therapy Patients With Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>- Prior first dose cetuximab , participant undergo sigmoidoscopy biopsy research purpose well collection blood sample . These test repeat day 16 21 . - After treatment begin , participant undergo follow every week ; history physical exam ; vital sign ; blood test . - On treatment week 1 , 2 3 : cetuximab give week . On week 4 9 : cetuximab give weekly ; continuous infusion 5-FU begin day 22 ; treatment radiation therapy Monday Friday . - It recommend participant undergo surgery 4 8 week completion therapy attempt remove tumor .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm adenocarcinoma rectum begin within 15cm anal verge determine sigmoidoscopy and/or colonoscopy , evidence distant metastatic disease . A complete colonoscopy cecum recommend prior initiate protocol therapy . Staging transrectal ultrasound endorectal coil MRI confirm clinical stage T3 T4 lymph node positive rectal adenocarcinoma Tumor Kras wildtype method choice respective institution ( test codon 12 13 ) Performance status : ECOG le equal 2 18 year age old No evidence metastatic disease abdominal/pelvic CT chest image Adequate bone marrow , renal , hepatic function outline protocol All patient evaluate surgeon consider candidate definitive surgery Coumadin heparin management line care indication permit . The INR monitor weekly patient take coumadin . Prior treatment malignancy Prior history pelvic radiation therapy Prior history 5FU base EGFR receptor inhibitor therapy Prior history allergic reaction monoclonal antibody Uncontrolled serious medical psychiatric illness Significant history uncontrolled cardiac disease Sexually active woman childbearing potential must use effective method birth control course study Unwilling agree pre postcetuximab sigmoidoscopy biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>5-FU</keyword>
	<keyword>cetuximab</keyword>
	<keyword>radiation</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>neoadjuvant therapy</keyword>
</DOC>